US20200354458A1 - Bifunctional Fusion Protein Targeting CD47 and PD-L1 - Google Patents
Bifunctional Fusion Protein Targeting CD47 and PD-L1 Download PDFInfo
- Publication number
- US20200354458A1 US20200354458A1 US16/765,008 US201716765008A US2020354458A1 US 20200354458 A1 US20200354458 A1 US 20200354458A1 US 201716765008 A US201716765008 A US 201716765008A US 2020354458 A1 US2020354458 A1 US 2020354458A1
- Authority
- US
- United States
- Prior art keywords
- fusion protein
- tumor
- iab
- cells
- sirpα
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 67
- 108010074708 B7-H1 Antigen Proteins 0.000 title claims abstract description 53
- 102000008096 B7-H1 Antigen Human genes 0.000 title claims abstract description 53
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 title claims abstract description 49
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 title claims abstract description 48
- 230000001588 bifunctional effect Effects 0.000 title claims abstract description 29
- 230000018883 protein targeting Effects 0.000 title abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 81
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 57
- 230000027455 binding Effects 0.000 claims abstract description 37
- 238000009739 binding Methods 0.000 claims abstract description 37
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims abstract description 17
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 230000001988 toxicity Effects 0.000 claims description 2
- 231100000419 toxicity Toxicity 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 abstract description 30
- 210000004881 tumor cell Anatomy 0.000 abstract description 26
- 230000000694 effects Effects 0.000 abstract description 18
- 230000008685 targeting Effects 0.000 abstract description 18
- 206010057249 Phagocytosis Diseases 0.000 abstract description 14
- 102100040678 Programmed cell death protein 1 Human genes 0.000 abstract description 14
- 230000008782 phagocytosis Effects 0.000 abstract description 14
- 238000011282 treatment Methods 0.000 abstract description 13
- 238000011081 inoculation Methods 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 4
- 230000006044 T cell activation Effects 0.000 abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 230000030741 antigen processing and presentation Effects 0.000 abstract description 3
- 230000015788 innate immune response Effects 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 2
- 231100000226 haematotoxicity Toxicity 0.000 abstract 1
- 230000002489 hematologic effect Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 51
- 241000699670 Mus sp. Species 0.000 description 49
- 108090000623 proteins and genes Proteins 0.000 description 43
- 102000004169 proteins and genes Human genes 0.000 description 41
- 108020005004 Guide RNA Proteins 0.000 description 16
- 210000001744 T-lymphocyte Anatomy 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 229940027941 immunoglobulin g Drugs 0.000 description 14
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 13
- 239000000427 antigen Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 11
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 9
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 230000007681 cardiovascular toxicity Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000012636 effector Substances 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000000750 progressive effect Effects 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 108700008625 Reporter Genes Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000002860 competitive effect Effects 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000005740 tumor formation Effects 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 229940125644 antibody drug Drugs 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 230000009137 competitive binding Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000003197 gene knockdown Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000001875 tumorinhibitory effect Effects 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010058590 CD47 Antigen Proteins 0.000 description 3
- 102000006355 CD47 Antigen Human genes 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 102000007614 Thrombospondin 1 Human genes 0.000 description 2
- 108010046722 Thrombospondin 1 Proteins 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 125000003147 glycosyl group Chemical group 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 102000044459 human CD47 Human genes 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 102100034612 Annexin A4 Human genes 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000924461 Homo sapiens Annexin A4 Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000742223 Homo sapiens Double-stranded RNA-specific editase 1 Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101710098610 Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 102100025372 Nuclear pore complex protein Nup98-Nup96 Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 101150036449 SIRPA gene Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000011398 antitumor immunotherapy Methods 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 238000001437 electrospray ionisation time-of-flight quadrupole detection Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 102000048776 human CD274 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 229940126546 immune checkpoint molecule Drugs 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Definitions
- the disclosure belongs to the field of biomedicine, more specifically, relates to a recombinant fusion protein targeting CD47 molecules and PD-L1 molecules.
- Tumor immune checkpoint therapy is a class of therapeutic methods for improving anti-tumor immune responses by modulating T cell activity through a series of pathways, such as co-inhibition or co-stimulation signals.
- the immune checkpoint plays an important role in regulating the amplitude and duration of the T-cell response and maintaining self-tolerance by co-stimulating and co-inhibiting molecules in the immune response process and generating “on” or “off” immune response signal, preventing damage to its own tissue.
- immune check point molecules include PD-1/PD-L1, CD47/SIRP ⁇ , CTLA-4/CD80/CD86, etc.
- PD-1 Programmed Cell Death Protein 1
- the PD-1 is an immune checkpoint protein with a negative regulation function, can prevent the activation of T cells, and plays an important role in reducing auto-immunity and promoting immune tolerance.
- the function of PD-1 is achieved by two pathways, one to promote apoptosis of antigen-specific T cells in lymph nodes, the other to reduce apoptosis of regulatory T cells (Treg, also called inhibitory T cells).
- PD-L1 (Programmed Death-Ligand 1) is one of the ligands of PD-1, also is a transmembrane protein, primarily expressed in placenta, heart, liver, lung, kidney, skeletal muscle and limited hematopoietic tissues, as well as some leukemia cell lines.
- PD-L1 binds to PD-1 to form a receptor-ligand complex and emit an inhibitory signal, including inducing the generation of IL-10 (inflammation and immunosuppressive factor), down-regulating anti-apoptotic gene bcl-2 to promote apoptosis of antigen-specific T cells, and inhibiting the proliferation of CD8+ T cells in lymph nodes, etc.
- IL-10 inflammation and immunosuppressive factor
- bcl-2 down-regulating anti-apoptotic gene bcl-2 to promote apoptosis of antigen-specific T cells, and inhibiting the proliferation of CD8+ T cells in lymph nodes, etc.
- PD-L1 is related to the inhibition of immune systems in some special situations, such as pregnancy, tissue transplantation, autoimmune disease, hepatitis, etc.
- PD-L1 can also bind to CD80 with a weaker affinity (K D value of 1.4 ⁇ M) besides being able to bind to PD-1 with a stronger affinity (K D value 770 nM).
- PD-L1 is found to be expressed on a variety of tumor cell surfaces so that tumor cells escape the killing of the immune system, and therefore can be used as targets for anti-tumor immunotherapy.
- CD47 leukocyte surface antigen 47
- TEP integrin-associated protein
- SIRP ⁇ Signal regulatory protein alpha
- SIRP-alpha is a trans-membrane receptor glycoprotein, specifically expressed on the surface of myeloid cells such as macrophages, dendritic cells, has a negative regulation effect on immunization, and is capable of inhibiting phagocytosis and T cell activation after binding with CD47.
- CD47 binds to the SIRP ⁇ and issues a “Don'T Eat Me” signal to the immune system.
- Such mechanism can protect the normal cells of the human body from being killed by the immune system. But such mechanism can also be utilized by tumor cells to achieve immune escape.
- immune check point drugs such as Ipilimumab (anti-CTLA-4), Nivolumab (anti-PD-1), Pembrolizumab (anti-PD-1), Atezolizumab (anti-PD-L1), Avelumab (anti-PD-L1), Durvalumab (anti-PD-L1) are currently approved for sale by the European or American Drug Administration.
- the PD-1/PD-L1 signal pathway acts only at the effect-phase of T cells, the affecting of anti-PD-1/PD-L1 drug requires the presentation of tumor antigens, which will be clinically ineffective for about 70% of low immunogenicity tumors, and needs to be used in combination with chemotherapy, radiation therapy and Mabs; Meanwhile, cancer cells can sometimes achieve immune escape through different pathways or routes, simple blockage of the PD-1/PD-L1 pathway may be transparent to the immune escape of some cancer cells.
- Antibodies targeted to CD47 have functions such as activating macrophages, enhancing T cell antigen presentation, and the like, and are functionally complementary to anti-PD-1/PD-L1.
- the expression of CD47 is not strictly tumor specific, and it is also expressed on the surface of healthy red blood cells.
- the tumor cell surface CD47 expression is only 3.3 times higher than normal cells. Therefore, in vivo use of CD47 antibody will often cause undesirable reaction such as anemia.
- a SIRP ⁇ mutant with high affinity to CD47 can only be administered as immune booster, in combination with other antibodies in the form of monomer without Fc.
- the effectiveness of the anti-PD-1/PD-L1 drug on the low immunogenicity heavy chain can be improved, and/or the blood toxicity of the CD47 targeting drug can be reduced, it will have great significance on improving the therapeutical effect on malignant tumors.
- a medicine is provided in the disclosure, said medicine combines the effects of two immune checkpoint drugs (anti-PD-1/PD-L1 and anti-CD47/SIRP ⁇ ) at different stages of anti-tumor immunization, forms a synergistic effect, generates higher efficacy and stronger therapeutical effect than that of a single medicine, thus improving the targeting property of the medicine to tumor cells, reducing the blood toxicity, and solving the insufficiency of the therapeutical effect or safety of the existing immune checkpoint medicine.
- two immune checkpoint drugs anti-PD-1/PD-L1 and anti-CD47/SIRP ⁇
- the disclosure provides a bifunctional fusion protein targeting CD47 and PD-L1, which can bind to PD-L1 to block PD-1/PD-L1 signaling pathway, and also can bind to CD47 to block CD47/SIRP ⁇ signaling pathway, have good cancer cell targeting and cytotoxicity (such as ADCC and CDC), and solve the problems on therapeutical effect and safety of the existing immune checkpoint antibody drugs.
- the disclosure also provides a method for reducing the toxicity of the CD47-targeting drug, which can reduce side reactions such as anemia caused by the binding of the CD47-targeting drug with red blood cells.
- a bifunctional fusion protein targeting CD47 and PD-L1 which can bind to both CD47 molecule and PD-L1 molecule.
- the fusion protein described above (designated as IAB) consists of two moieties linked by disulfide bonds ( FIG. 2 ), wherein one can bind to CD47, formed by linking SIRP ⁇ high affinity mutant (designated as SIRP ⁇ -m) to an antibody Fc segment (designated as SIRP ⁇ -m-Fc); the other can bind to PD-L1, formed by linking a light chain (designated as anti-PDL1-L) and a heavy chain (designated as anti-PDL1-H) of anti-PD-L1 antibody by disulfide bond.
- Both the antibody Fc segments contained in SIRP ⁇ -m-Fc and anti-PDL1-H peptide chains are IgG types, preferably IgG1 subtypes;
- a Knob-in-Hole structure is introduced into the Fc segments of the SIRP ⁇ -m-Fc and the anti-PDL1-H peptide chains.
- the “Knob-in-Hole structure” can be achieved by the following: introducing 2 amino acid mutations into the Fc segment of the anti-PDL1-H peptide chain (T366W, S354C) (based on the IgG innate sequence), forming protruded Knob structure.
- the SIRP ⁇ -m-Fc peptide chain has the amino acid sequence as set forth in SEQ ID NO: 1; the anti-PDL1-L peptide chain has the amino acid sequence as set forth in SEQ ID NO: 2, and the anti-PDL1-H peptide chain has the amino acid sequence as set forth in SEQ ID NO: 3.
- the IABs can be expressed by genetically engineered CHO (Chinese hamster ovary) cells. Particularly, IABs are expressed by CHO-K1 cells, and the expression vector used is pcDNA3.1(+).
- the SIRP ⁇ -m-Fc is encoded by the nucleotide sequence as set forth in SEQ ID NO: 4; the light chain of the anti-PDL1-L is encoded by the nucleotide sequence as set forth in SEQ ID NO: 5; the anti-PDL1-H is encoded by the nucleotide sequence as set forth in SEQ ID NO: 6; and the sequences as set forth in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6 are inserted by genetic recombination into open reading frame (ORF) of the pcDNA3.1(+), using the constructed expression vector containing the target protein coding sequence to transfect CHO-K1 cells, then screening to obtain the cell strains capable of stably expressing the IAB for the expression of
- the above-mentioned bifunctional fusion protein targeting CD47 and PD-L1 can be used for manufacturing tumor drugs and immunoregulation drugs.
- Antibodies are produced by the immune system of the body stimulated by antigens.
- Antibodies are immunoglobulins produced by plasma cell differentiated from B lymphocytes. An antibody is capable of carrying out specific binding reaction with corresponding antigen.
- Antibodies can also be prepared by in vitro methods such as hybridoma, genetic engineering and the like. According to physical and chemical properties and biological functions, the antibodies can be divided into 5 categories, that is, IgM, IgG, IgA, IgE, and IgD.
- the IgG (Immunoglobulin G) antibody is the major antibody component in serum, adding up to about 75% of the serum immunoglobulins, and is also the primary type of existing antibody drug inside China and abroad.
- a complete IgG-type antibody consists of four peptide chains ( FIG. 1 ), including symmetrically two heavy chains and two light chains, and linked together by disulfide bonds.
- Each light chain consists of variable regions (VLs) and constant regions (CLs), and the heavy chain consists of variable regions (VHs) and constant regions (CHs).
- the heavy chain constant regions of the IgG-type antibody can be divided into three parts: CH1, CH2, and CH3.
- variable regions (VLs and VHs) of the light chain and heavy chain are the moieties binding to the antigen, and the heavy chain CH2, CH3 regions have immune effecting functions such as binding to complement, Fc receptor, protein A, and induces ADCC (antibody dependent cell-mediated cytotoxicity), CDC (complement dependent cytotoxicity) and the like;
- the CH2 region has a N-linked glycosylation site N297, the glycosylation modification at this site has an important influence on the cytotoxicity of the antibody and the like, and the removal of the said glycosylation will make the antibody lose the function of inducing cytotoxicity such as ADCC.
- the light chain is linked to the heavy chain through the disulfide bond of the CL and the CH1 regions; the heavy chain is provided with a hinge region between CH1 and CH2 regions, which is easy to stretch and bend, and the two heavy chains of one antibody are connected via disulfide bonds in the hinge region.
- two Fab fragment of antigen binding
- 1 Fc fragment crystallizable
- Human IgG has four subtypes: IgG1, IgG2, IgG3 and IgG4, wherein IgG1 has strong ability to induce ADCC and CDC effects and longer serum half-life, and is the most common antibody subtype of antibody drug, such as Rituximab (anti-CD20), Trastuzumab (anti-HER2); IgG 2 and IgG 4 have weaker abilities to induce ADCC and CDC effects and longer serum half-life, which can be used to develop antibody drugs whose major acting mechanisms are signal blocking, regulatory or neutralizing, such as Nivolumab (anti-PD-1), Pembrolizumab (anti-PD-1).
- the fusion protein consists of a CD47 binding moiety and a PD-L1 binding moiety linked by a disulfide bond; wherein the CD47 binding moiety is formed by linking a SIRP ⁇ mutant (SIRP ⁇ -m) having a high affinity for CD47 and an antibody Fc segment (primarily CH2, CH3 region), and the PD-L1 binding moiety is formed by linking a heavy chain and a light chain of anti-PD-L1 antibody by disulfide bond.
- SIRP ⁇ -m SIRP ⁇ mutant
- SIRP ⁇ mutant (SIRP ⁇ -m) in the fusion protein can bind to the CD47 antigen at much higher affinity than the endogenous natural SIRP ⁇ protein, so that the binding of the natural SIRP ⁇ on the surface of the macrophage and the CD47 antigen on the surface of cancer cells can be blocked, to avoid the inhibition and escape of cancer cells to the phagocytosis of macrophages.
- the anti-PD-L1 antibody is capable of binding to PD-L1 (highly expressed on the surface of cancer cells) with high affinity, to block the binding of “PD-L1 on the surface of cancer cells to PD-1 on the surface of activated T cells, so that avoid the inhibition and escape of cancer cells to T cells.
- PD-L1 is more highly expressed on cancer cell surface and the targeting property of the anti-PD-L1 is stronger, which make up the deficiencies that the CD47 specificity is poor and the anti-CD47 is severe in blood toxicity.
- the blood toxicity of the IAB is much lower than that of the fusion protein consisted of SIRP ⁇ -m and Fc, and with better safety.
- the bifunctional fusion protein targeting CD47 and PD-L1 of the present disclosure serves both in early innate immunity as to activate macrophage phagocytosis of tumor cells and to improve tumor antigen presentation and in acquired immunity as to promote tumor-specific T cell activation and proliferation, while compared with a single anti-CD47 drug, with better tumor cell targeting and less blood toxicity.
- Animal experiments shows that the bifunctional fusion protein has better anti-tumor therapeutical effect and blood safety than anti-PD-L1 or anti-CD47 alone. And, the subject with tumor disappeared after IAB treatment can have immunity against the same type of tumor cells inoculated later.
- FIG. 1 is a schematic (not to scale) illustration of the genomic loci of the representative Cas13e and Cas13f families members.
- the Cas coding sequences (long bars with pointed end), followed by the multiple nearby direct repeat (DR) (short bars) and spacer sequences (diamonds) are shown.
- DR direct repeat
- FIG. 2 shows putative secondary structures of the DR sequences associated with the respective Cas13e and Cas13f proteins. Their coding sequences, from left to right, are represented by SEQ ID NOs: 8-14, respectively.
- FIG. 3 shows a phylogenetic tree for the newly discovered Cas13e and Cas13f effector proteins of the invention, as well as the related previously discovered Cas13a, Cas13b, Cas13c, and Cas13d effector proteins.
- FIG. 4 shows the domain structures for the Cas13a-Cas13f proteins. The overall sizes, and the locations of the two RXXXXH motifs on each representative member of the Cas proteins are indicated.
- FIG. 5 shows a predicted 3D structure of the Cas13e.1 effector protein.
- FIG. 6 is a schematic drawing showing that the three plasmids, encoding (1) a Cas13e effector protein, (2) a coding sequence for the guide RNA (gRNA) which can produce the guide RNA that is complementary to the mCherry mRNA and that can form a complex with the Cas13e effector protein, and (3) the mCherry reporter gene, respectively, can be transfected to a cell to express their respective gene products, resulting in the degradation of the reporter mCherry mRNA.
- gRNA guide RNA
- FIG. 7 shows knock-down of mCherry mRNA by guide RNA complementary to the mCherry mRNA, as evidenced by reduced mCherry expression under fluorescent microscope.
- a non-targeting (NT) guide RNA that does not hybridize with/bind to the mCherry mRNA failed to knock-down mCherry expression.
- FIG. 8 shows about 75% knock-down of mCherry expression in experiments in FIG. 6 .
- FIG. 9 shows that Cas13e utilizes a guide RNA having a DR sequence at the 3′ end (as opposed to a DR sequence at the 5′-end of the guide RNA).
- FIG. 10 shows the correlation between spacer sequence length and specific (guide RNA-dependent) RNase activity against target RNA relative to non-targeting (NT) control.
- FIG. 11 shows the correlation between spacer sequence length and non-specific/collateral (guide RNA-independent) RNase activity against target RNAs relative to non-targeting (NT) control.
- FIG. 12 shows that dCas13e.1-ADAR2DD fusion has RNA base editing activity.
- three plasmids encoding (1) a dCas13e (RNase dead) protein fused to the single-base RNA editor ADAR2DD, (2) a coding sequence for the guide RNA (gRNA) which can produce the guide RNA that is complementary to a mutant mCherry mRNA having a G-to-A point mutation and that can form a complex with the dCas13e effector protein, and (3) the mutant mCherry reporter gene encoding the mCherry mRNA having the G-to-A point mutation, respectively, can be transfected to a cell to express their respective gene products.
- gRNA guide RNA
- the mutant mCherry mRNA normally cannot produced a fluorescent mCherry protein due to the point mutation.
- the fused ADAR2DD base editor converts A to I (G equivalent), thus restoring the ability of the mRNA to encode a fluorescent mCherry protein.
- FIG. 13 shows restored expression of mCherry as a result of successful RNA base editing.
- plasmid encoding mutant mCherry (mCherry*) alone failed to express fluorescent mCherry.
- Plasmid encoding dCas13e-ADAR2DD base editor alone also failed to express fluorescent mCherry.
- Plasmid encoding either gRNA-1 or gRNA-2 alone (which also expresses a GFP reporter) also failed to express fluorescent mCherry, though GFP was expressed prominently.
- GFP reporter expression when all three plasmids were transfected into the same cell, significant fluorescent mCherry expression was observed (together with GFP reporter expression).
- FIG. 14 shows the relevant segment of the mutant mCherry gene having the premature stop codon TAG, the sequence for the two gRNA that can be complexed with the dCas13e-ADAR2DD RNA base editor, and the “corrected” TGG codon.
- FIG. 15 is a schematic (not to scale) drawing showing the series of progressive C-terminal deletion constructs for dCas13e.1 fused to the ADAR2DD RNA base editor (shown as “ADAR2”), as well as other transcriptional control elements.
- ADAR2 ADAR2DD RNA base editor
- FIG. 16 shows the percentage results of mCherry mutant conversion back to wild-type mCherry, for the series of C-terminal deletion mutants in FIG. 15 .
- FIG. 17 is a schematic (not to scale) drawing showing the series of progressive C-terminal and optional N-terminal deletion constructs for dCas13e.1 fused to the ADAR2DD RNA base editor.
- FIG. 18 shows the percentage results of mCherry mutant conversion back to wild-type mCherry, for selected C- and N-terminal deletion mutants in FIG. 17 .
- FIG. 19 shows the series of plasmids encoding Cas13a, Cas13b, Cas13d, Cas13e.1 and Cas13f.1, the mCherry reporter gene, as well as either the ANXA4-targeting gRNA coding sequence, or a non-targeting gRNA as control.
- FIG. 20 shows efficient knock-down of ANXA4 expression by Cas13e.1, Cas13f.1, Cas13a, as well as Cas13d.
- nucleic acids as set forth in SEQ ID NO: 4 (encoding a fusion peptide formed by linking SIRP ⁇ mutant with antibody Fc segment, with Hole structure formed by the mutation of Y349 C, T366S, L368 A and Y407 V), SEQ ID NO: 5 (encoding anti-PD-L1 antibody light chain), and SEQ ID NO: 6 (encoding anti-PD-L1 antibody heavy chain, with Knob structure formed by mutations of T366W and S354C), corresponding DNA fragments were synthesized respectively, and were inserted into the pcDNA3.1 (+) vector by genetic engineering technology.
- the expression vectors constructed were called as pcDNA3.1-SIRP ⁇ -m-Fc, pcDNA3.1-antiPDL1-L and pcDNA3.1-antiPDL1-H.
- Three expression vectors were co-transfected with liposomes into CHO-K1 host cells, and the transfected cells were cultured in DMEM complete medium containing 20% fetal bovine serum (FBS) (available from Invitrogen Inc.) for 24 hours, and then screened under pressure in selection medium containing 1 mg/ml G418, continued for incubation for 2 weeks.
- FBS fetal bovine serum
- Subcloning screening was carried out by limited dilution assay; comparing the content of the target protein in the cell culture supernatant by Dot-Blot assay (the supernatant is blotted on a nitrocellulose membrane, and then adding a horseradish peroxidase (HRP)-labeled mouse anti-human Ig antibody, and colored by diaminobenzidine DAB after sealing), and screening a clone with the highest expression of the target protein IAB as the expression cell strain.
- HRP horseradish peroxidase
- the expression cell strains were passaged in a mixed culture medium consisting of DMEM complete medium and CHOM-B1 serum-free medium (available from Shanghai SINOMAB biotech Ltd., Shanghai) of different ratios, and the ratio of complete medium was reduced from 100% to 0%, and then continued the culture in CHOM-B1 serum-free medium for passage.
- DMEM complete medium obtained from Shanghai SINOMAB biotech Ltd., Shanghai
- CHOM-B1 serum-free medium available from Shanghai SINOMAB biotech Ltd., Shanghai
- the bifunctional fusion protein IAB was purified by Protein A affinity chromatography column method, a balance liquid of 10 times of column volume (20 mM phosphate buffer solution containing 150 mM NaCl, pH 7.0) was used for balancing the column body and then loading the supernatant. After loading, the column was washed by balance buffer of 5-10 times of the column volume to the conductance balance. Elution was then carried out with eluent (50 mM citric acid buffer, pH 3.5) and the elution peak was collected after OD 280 was greater than 200 mAU.
- eluent 50 mM citric acid buffer, pH 3.5
- the complete protein molecular weight of the target protein IAB was about 120 kDa; in the reduced SDS-PAGE electrophoresis diagram of FIG. 4 , the partial molecular weight of the heavy chain of the IAB protein (anti-PDL1-H) was about 50 kDa, and the fusion peptide chain (SIRP ⁇ -m-Fc) has a partial molecular weight of about 40 kDa, the light chain (anti-PDL1-L) moiety was 25 kDa, which is substantially consistent with the theoretical value.
- the fusion peptide chain (SIRP ⁇ -m-Fc) in FIG. 4 exhibits two bands of about 40 kD, which may be associated with the effect of post-translational modifications and spatial structure on electrophoresis.
- the expressed and purified IAB fusion protein was desalted into 50 mM NH 4 HCO 3 solution, and the desalted protein solution was quantified by UV (50 mM NH 4 HCO 3 as blank control with an extinction coefficient of 1.60).
- the desalted protein solution was added to 50 mM NH 4 HCO 3 , diluted to 1 mg/mL for loading.
- Liquid Phase Equipment, Waters ACQUITY UPLC system Liquid Phase Equipment, Waters ACQUITY UPLC system; chromatographic measures: BEH 300.4 C4 1.7 ⁇ m, 2.1 ⁇ 50 mm; column temperature 60° C.; sample chamber temperature 15° C.; flow rate 0.4 ml/min; mobile phase A: 99.9% water+0.1% formic acid; mobile phase B: 99.9% acetonitrile+0.1% formic acid; loading volume: 5 ⁇ L; detector ESI-Q-TOF.
- mass spectrometry equipment Waters; source temperature 120; capillary voltage setting: 3000V; primary cone voltage setting: 40 V; secondary cone voltage setting: 4V; cone gas flow rate: 50 L/H; acquisition time range 3-15 min; desolvation temperature setting: 400° C. quality calibration range selection: 500-3000m/z; acquisition quality range selection 500-3000 m/z; scan time: 1.0 S.
- the results are shown in FIG. 5 .
- the main sugar types modified after IAB translation are ⁇ 2KG0F(2)(molecular weight 113785), ⁇ 2KG0FG1F (molecular weight 113949), ⁇ 2KG1F(2)(molecular weight 114114), G0G2F (114216), without significant production of undesirable sugar types. Its molecular weight and theoretical molecular weight (post-translational modification) are consistent.
- nucleotide sequences of SEQ ID NO:9 (encoding the fusion peptide formed by linking SIRP ⁇ high affinity mutant SIRP ⁇ -m and IgG1 antibody Fc, but without “Hole” structure) and SEQ ID NO: 10 (encoding heavy chain of anti-PD-L1 antibody, but without “Knob” structure, and the Fc glycosyl modification was removed by N297A mutation), corresponding DNA fragments were synthesized, and inserted into the pcDNA3.1 vector respectively to construct expression vectors pcDNA3.1-SIRP ⁇ -m-Fc′ and pcDNA3.1-antiPDL1-H ‘.
- the pcDNA3.1-SIRP ⁇ -m-Fc’ was transfected into CHO-K1 expression host cells according to the method of Example 1.
- the strains of high expression were screened, and the control SIRP ⁇ -m-Fc fusion protein was prepared by using the protein expression and purification methods in Examples 1 and 2, and the protein was named as SIRP ⁇ -m-Fc′ with the amino acid sequence as set forth in SEQ ID NO: 7.
- a control anti-PD-L1 antibody was prepared by co-transfect pcDNA3.1-antiPDL1-H′ and pcDNA3.1-antiPDL1-L prepared in Example 1 into CHO-K1 expression host cell and screen cell strain with high expression. Protein expression and purification method in Examples 1 and 2 was used to prepare said control antiPD-L1 antibody, which was called anti-PDL1′ with the amino acid sequence as set forth in SEQ ID NO: 8.
- Biotin labeled anti-PDL1′ was used.
- the recombinant expressed human PD-L1-Fc fusion protein was diluted with 0.1M NaHCO 3 solution (pH9.6) to 5 ⁇ g/ml, and coated the microwell plates at 100 ⁇ l/well, washed, blocked, and then biotin-labeled anti-PDL1′ and gradient diluted competitors were added into each well, wherein the competitors were unlabeled anti-PDL1′ or IAB proteins prepared in Example 2.
- the competitor concentrations were respectively initiated from 1 ⁇ g/ml, and 2-fold diluted. Each concentration was repeated in triplicate wells, incubated at 37° C. for 1 hour, and then the reaction liquid was discarded, plates were washed.
- Avidin-labeled horseradish peroxidase (Avidin-HRP) and substrate TMB were added for developing, OD450 nm absorbence was measured. The results were plotted and shown in FIG. 6 .
- the x axis is competitor concentration (ng/ml) and the y axis is OD value, hollow triangle is competition data of anti-PDL1′, and the solid circle is competition data of IAB.
- the binding of IAB protein to CD47 was determined by the same method,
- the antigen coating microwell plate was a recombinant expressed human CD47 protein, Biotin-labeled SIRP ⁇ -m-Fc′ and gradient diluted competitors were added.
- the competitors were unlabeled SIRP ⁇ -m-Fc′ or IAB proteins prepared in Example 2.
- the competitor concentrations were respectively initiated from 1 ⁇ g/ml, and 2-fold diluted. Each concentration was repeated in triplicate wells, after incubation, horseradish and TMB were used for developing, OD450 nm absorbance was measured. The results were plotted and shown in FIG. 7 .
- the x axis is competitor concentration (ng/ml) and the y axis is OD value
- hollow triangle is competition data of anti-PDL1′
- the solid circle is competition data of IAB.
- FIGS. 6 and 7 illustrate that fusion protein IAB has binding activity to both target antigens PD-L1 and CD47 at the same time, and recognizes the same binding epitope as prototype antibody or ligand, having competitive binding capacity.
- the IAB protein and binding site are “monovalent”, its affinity is reduced compared to the prototype antibody or ligand.
- IAB protein The binding of IAB protein to MC38 cells (mouse colon cancer cells), HL60 cells (human leukemia cells) was detected using flow cytometry and the results are shown in FIGS. 19 and 20 (dotted lines represent blank controls, and solid lines represent IAB proteins, short dashed lines represent anti-PDL1′, and long dashed lines represent SIRP ⁇ -m-Fc′) using SIRP ⁇ -m-Fc′ and anti-PDL1′ as control.
- the results illustrate that the IAB protein can bind to the surface of MC38 cell and the HL60 cells.
- PBMC peripheral blood mononuclear cells
- the cell status was observed by an inverted microscope on a daily basis. The supernatant was taken after 72 hours, and the amount of IL-2 secretion was determined by ELISA. Experimental results are shown in FIG. 8 .
- the stimulation of PBMC cells by SEB can increases its IL-2 secretion amount and exhibits a dose-dependent profile within a certain concentration range of SEB (0-100 ng/mL).
- the IL-2 amount of IAB and anti-PDL1′ groups at different SEB concentrations are significantly higher than SIRP ⁇ -m-Fc′. It is proved that the IAB can activate T cells in vitro.
- 2 ⁇ 10 6 mouse colon cancer cell strain MC 38 was incubated with 2000 ⁇ L of 5 ⁇ M CSFE (2-carboxyfluorescein diacetate succinimidyl ester, a live fluorescent dye) solution at 37° C. for 20 min, and then 10 mL of complete medium was added, incubated for 5 min to remove unbound CSFE in the solution.
- the marked tumor cells were collected by centrifugation and resuspended in complete medium to prepare tumor cell suspension at a concentration of 1 ⁇ 10 6 /mL.
- Macrophages were digested with Trypsin and then collected by centrifugation, washed twice with PBS. After counted on Hemocytometer, the cell density was adjusted to 1 ⁇ 10 6 /mL and resuspended in PBS buffer containing 1% FBS. Cell suspension was then added to flow cytometry assay tube (100 ⁇ L/tube), centrifuged to discard supernatant, and 100 ⁇ L of fluorescent labeled antibody (PE-labeled anti-mouse F4/80 antibody) was added to the flow cytometry tube, incubated on ice in dark for 45 min, washed twice with PBS buffer containing 1% FBS and assay in the suspension in 300 ⁇ l PBS.
- fluorescent labeled antibody PE-labeled anti-mouse F4/80 antibody
- PE mono-positive was macrophages
- CSFE mono-positive was MC38 tumor cells
- PE and CSFE double-positive cells were macrophages for phagocytosis of MC38 cells. Phagocytosis rates of macrophages under the action of different proteins were calculated.
- the macrophage phagocytosis efficiency in the co-culture system is substantially the same ( ⁇ 10%) when comparing anti-PDL1′ to the negative control (IgG1). While for positive control (SIRP ⁇ -m-Fc′) and IAB fusion protein, the phagocytosis efficiency of macrophages in the co-culture system can be greatly improved, wherein the phagocytosis promoting ability of the IAB fusion protein (36%) is lower than SIRP ⁇ -m-Fc′ (49%), while anti-PDL1′ does not have the ability to promote the macrophage phagocytosis.
- mouse myeloid cells were isolated and cultured for 7-10 days with the induction of 50 ng/ml M-CSF to prepare mouse myeloid-derived macrophages.
- 5 ⁇ 10 4 mouse myeloid-derived macrophages were mixed with 2 ⁇ 10 5 CFSE-labeled MC38 tumor cells, adding into IAB fusion protein, negative control (IgG1) and positive control SIRP ⁇ -m-Fc′, incubated at 37° C. for 2 hours, photographed with an inverted microscope, and macrophages with green fluorescence in the image were macrophages after phagocytosis of tumor cells.
- IgG1 negative control
- SIRP ⁇ -m-Fc′ positive control
- FIG. 10 macrophages ( FIG. 10 a ) adhere to the wall and stretch out the pseudopods in the negative control group added with IgG1 ( FIG. 10 a ), almost no macrophages phagocytized tumor cells (green fluorescence).
- FIG. 10 c positive control group SIRP ⁇ -m-Fc′
- FIG. 10 b the macrophages phagocytized tumor cells (green fluorescence) (indicated by the black arrows).
- the above results again verify that the IAB fusion protein has the ability to promote macrophage phagocytosis of tumor cells in vitro.
- the black squares in FIG. 11 are data for IAB fusion proteins.
- the black solid circles are the data of SIRP ⁇ -m-Fc′, and the black triangles are the data of anti-PDL1′.
- mice 15 healthy Balb/c mice (6-8 weeks) were randomly divided into 3 groups (5 per group) by weight (on average about 20 g). Each group of mice were administered intraperitoneally (IAB, SIRP ⁇ -m-Fc′, or i.v. human IgG) at a dose of 100 mg/kg; after 24 hours of administration, mice were sampled for blood through the orbital about 500 ⁇ l into EP tube, and 1% heparin sodium 10 ⁇ L was added immediately to prevent clotting. Mouse blood analysis was performed at Shanghai Model Organisms Center, Inc.
- red blood cell content (9.1 ⁇ 10 12 /L), HCT (43.0%), hemoglobin (137.8 g/L) of the experimental group injected with IAB protein do not have significant difference from the red blood cell content (9.4 ⁇ 10 12 /L), HCT (42.56%), and hemoglobin (142.4 g/L) of the control group injected with human IgG.
- the experimental results show that after the control group was administered with irrelevant antibodies (i.v. human IgG1), the tumor was in progressive growth, and the average volume of tumor on day 21 reached 1472 mm 3 at the end of observation (21 days after inoculation), the control group and the SIRP ⁇ -m-Fc′ treatment group mice were didazzling, thin, wrinkled skin and with slow movement.
- the tumor on the back of the anti-PDL1′ and IAB treatment group mice were shrunk to various extent.
- the average tumor size of anti-PDL1′ treatment group mice is 289 mm 3 .
- the average tumor size of IAB treatment group mice is 67 mm 3 , and tumor in some of the mice completely disappeared, indicating that IAB fusion protein has better anti-tumor effect than prototype protein (anti-PDL1′ and SIRP ⁇ -m-Fc′) in the treatment of MC38 tumor model.
- the tumor suppressing effect is with the following order: IAB>anti-PDL1′>SIRP ⁇ -m-Fc′. The result shows that under same dosage and with same administration route, the IAB fusion protein has a “synergistic effect” of tumor suppression.
- mice treated with IAB fusion protein treatment groups whose tumor completely disappeared (touching inoculation sites with no accessible tumors) and healthy BALB/c mice were subjected to MC38 secondary inoculation experiment.
- MC38 tumor cells were inoculated subcutaneously on the other side of the primary inoculation site in mice, with the inoculum size of 2 ⁇ 10 5 cells/animal.
- the mice were sacrificed by cervical dislocation. The observation usually lasts 21 days.
- the experimental results are shown in FIG. 16 .
- mice healthy Balb/c mice
- the tumor was in progressive growth, and the average volume of tumor on day 21 reached 1453 mm 3 ; however, after the mice cured with IAB fusion protein were inoculated with MC38, no accessible tumor (less than 30 mm 3 ) can be found at the inoculation site within 21 days. Only one mouse had evidence of tumor growth on day 10, but disappeared itself later.
- the above results showed that it is possible that the cured mice have alleviate the tumor adaptability for MC38 and the inhibitory state of innate immunity, and the antigen-specific T cells generated after the adaptive immune activation can inhibit the tumor formation of the MC38 tumor cells for a second time.
- mice were inoculated subcutaneously to 15 BALB/C healthy female mice of 6-8 weeks at 2 ⁇ 10 5 cells.
- mice were grouped according to the mean tumor volume into three groups, each group consisting of 5 mices, and assigned as experimental group, control group 1, and control group 2.
- Experimental group were injected with Clophosome (a macrophage remover, available from Shanghai BangLv Biotech Co., Ltd) at 200 ⁇ L/mouse, then 100 ⁇ l/mouse every other day; IAB fusion protein were injected into the tumor at 10 mg/kg dose on day 7 and day 10.
- Clophosome a macrophage remover, available from Shanghai BangLv Biotech Co., Ltd
- Control group 1 were injected with blank liposome instead of Clophosome to inject mouse, and IAB fusion protein were injected into the tumor at 10 mg/kg dose on day 7 and day 10;
- Control Group 2 were injected with blank liposome instead of Clophosome, and irrelevant human IgG antibody was injected into the tumor at 10 mg/kg dose on day 7 and day 10.
- the mice were sacrificed by cervical dislocation. The observation usually lasts 21 days.
- the experimental results are shown in FIG. 17 .
- mice without removal of macrophages were injected with irrelevant antibodies (that is, control group 2), the subcutaneous tumor was in progressive growth, and the average volume of tumor on day 20 reached 1419 mm 3 .
- the tumor in the mice without removal of macrophages was effectively inhibited, the average size of tumor on day 20 was only 55.8 mm 3 .
- the mice with removal of macrophage that is, the experimental group
- the average tumor size on day 21 is 587 mm 3
- the tumor inhibitory effect is significantly lower than the healthy mice group (control group 1).
- the above experiment suggests that the in vivo tumor inhibitory effect of IAB fusion protein depends on the innate immune cells (Macrophages).
- mice Each BALB/c mouse was injected twice weekly with anti-CD8 antibodies or irrelevant IgG antibodies (200 ⁇ g/mouse/time) to remove CD8+ positive T cells in mice.
- MC38 tumor cells were inoculated subcutaneously to 5 Balb/c mice with the removal of CD8+ T cells (experimental group), 10 healthy female mice (divided into control groups 1 and 2) of 6-8 weeks at 2 ⁇ 10 5 cells.
- experimental group and control group 1 were injected with IAB fusion protein in tumor at 10 mg/kg dose on day 7 and day 10.
- Control group 2 was injected with irrelevant human IgG antibodies at 10 mg/kg dose in tumor on day 7 and day 10.
Abstract
Description
- The disclosure belongs to the field of biomedicine, more specifically, relates to a recombinant fusion protein targeting CD47 molecules and PD-L1 molecules.
- The “immune escape” of cancer cells is believed to be the primary mechanism for tumor onset, development, and drug resistance. Tumors generally protect themselves from the removal of immune systems by directly or indirectly inhibiting the signal of T cells. Tumor immune checkpoint therapy is a class of therapeutic methods for improving anti-tumor immune responses by modulating T cell activity through a series of pathways, such as co-inhibition or co-stimulation signals.
- The immune checkpoint plays an important role in regulating the amplitude and duration of the T-cell response and maintaining self-tolerance by co-stimulating and co-inhibiting molecules in the immune response process and generating “on” or “off” immune response signal, preventing damage to its own tissue. Currently discovered immune check point molecules include PD-1/PD-L1, CD47/SIRPα, CTLA-4/CD80/CD86, etc.
- (1) PD-1/PD-L1
- PD-1 (Programmed Cell Death Protein 1) is a cell surface receptor expressed on the surface of T cells and the pre-B cells, upregulated on activated T cells, capable of binding to both PD-L1 and PD-L2 ligands. The PD-1 is an immune checkpoint protein with a negative regulation function, can prevent the activation of T cells, and plays an important role in reducing auto-immunity and promoting immune tolerance. The function of PD-1 is achieved by two pathways, one to promote apoptosis of antigen-specific T cells in lymph nodes, the other to reduce apoptosis of regulatory T cells (Treg, also called inhibitory T cells).
- PD-L1 (Programmed Death-Ligand 1) is one of the ligands of PD-1, also is a transmembrane protein, primarily expressed in placenta, heart, liver, lung, kidney, skeletal muscle and limited hematopoietic tissues, as well as some leukemia cell lines. PD-L1 binds to PD-1 to form a receptor-ligand complex and emit an inhibitory signal, including inducing the generation of IL-10 (inflammation and immunosuppressive factor), down-regulating anti-apoptotic gene bcl-2 to promote apoptosis of antigen-specific T cells, and inhibiting the proliferation of CD8+ T cells in lymph nodes, etc. PD-L1 is related to the inhibition of immune systems in some special situations, such as pregnancy, tissue transplantation, autoimmune disease, hepatitis, etc. PD-L1 can also bind to CD80 with a weaker affinity (KD value of 1.4 μM) besides being able to bind to PD-1 with a stronger affinity (KD value 770 nM).
- PD-L1 is found to be expressed on a variety of tumor cell surfaces so that tumor cells escape the killing of the immune system, and therefore can be used as targets for anti-tumor immunotherapy.
- (2) CD47/SIRPα
- CD47 (leukocyte surface antigen 47), also called as integrin-associated protein (TAP), is a transmembrane protein, associated with membrane integrins, also binds to Thrombospondin-1 (TSP-1), Signal regulatory protein alpha (SIRPα). CD47 is widely expressed on human somatic cells and overexpressed on various tumor cells, participating in various cell activities such as apoptosis, proliferation, adhesion, migration and the like.
- SIRP-alpha is a trans-membrane receptor glycoprotein, specifically expressed on the surface of myeloid cells such as macrophages, dendritic cells, has a negative regulation effect on immunization, and is capable of inhibiting phagocytosis and T cell activation after binding with CD47.
- CD47 binds to the SIRPα and issues a “Don'T Eat Me” signal to the immune system. Such mechanism can protect the normal cells of the human body from being killed by the immune system. But such mechanism can also be utilized by tumor cells to achieve immune escape.
- A number of immune check point drugs, such as Ipilimumab (anti-CTLA-4), Nivolumab (anti-PD-1), Pembrolizumab (anti-PD-1), Atezolizumab (anti-PD-L1), Avelumab (anti-PD-L1), Durvalumab (anti-PD-L1) are currently approved for sale by the European or American Drug Administration.
- However, the following problems still exist in the immune check point drugs:
- Since the PD-1/PD-L1 signal pathway acts only at the effect-phase of T cells, the affecting of anti-PD-1/PD-L1 drug requires the presentation of tumor antigens, which will be clinically ineffective for about 70% of low immunogenicity tumors, and needs to be used in combination with chemotherapy, radiation therapy and Mabs; Meanwhile, cancer cells can sometimes achieve immune escape through different pathways or routes, simple blockage of the PD-1/PD-L1 pathway may be inutile to the immune escape of some cancer cells.
- Antibodies targeted to CD47 have functions such as activating macrophages, enhancing T cell antigen presentation, and the like, and are functionally complementary to anti-PD-1/PD-L1. However, the expression of CD47 is not strictly tumor specific, and it is also expressed on the surface of healthy red blood cells. The tumor cell surface CD47 expression is only 3.3 times higher than normal cells. Therefore, in vivo use of CD47 antibody will often cause undesirable reaction such as anemia. To reduce side effects, a SIRPα mutant with high affinity to CD47 can only be administered as immune booster, in combination with other antibodies in the form of monomer without Fc.
- If the effectiveness of the anti-PD-1/PD-L1 drug on the low immunogenicity heavy chain can be improved, and/or the blood toxicity of the CD47 targeting drug can be reduced, it will have great significance on improving the therapeutical effect on malignant tumors.
- A medicine is provided in the disclosure, said medicine combines the effects of two immune checkpoint drugs (anti-PD-1/PD-L1 and anti-CD47/SIRPα) at different stages of anti-tumor immunization, forms a synergistic effect, generates higher efficacy and stronger therapeutical effect than that of a single medicine, thus improving the targeting property of the medicine to tumor cells, reducing the blood toxicity, and solving the insufficiency of the therapeutical effect or safety of the existing immune checkpoint medicine.
- In particular, the disclosure provides a bifunctional fusion protein targeting CD47 and PD-L1, which can bind to PD-L1 to block PD-1/PD-L1 signaling pathway, and also can bind to CD47 to block CD47/SIRPα signaling pathway, have good cancer cell targeting and cytotoxicity (such as ADCC and CDC), and solve the problems on therapeutical effect and safety of the existing immune checkpoint antibody drugs.
- The disclosure also provides a method for reducing the toxicity of the CD47-targeting drug, which can reduce side reactions such as anemia caused by the binding of the CD47-targeting drug with red blood cells.
- The technical solutions of the present disclosure are as follows:
- A bifunctional fusion protein targeting CD47 and PD-L1, which can bind to both CD47 molecule and PD-L1 molecule.
- The fusion protein described above (designated as IAB) consists of two moieties linked by disulfide bonds (
FIG. 2 ), wherein one can bind to CD47, formed by linking SIRPα high affinity mutant (designated as SIRPα-m) to an antibody Fc segment (designated as SIRPα-m-Fc); the other can bind to PD-L1, formed by linking a light chain (designated as anti-PDL1-L) and a heavy chain (designated as anti-PDL1-H) of anti-PD-L1 antibody by disulfide bond. - Both the antibody Fc segments contained in SIRPα-m-Fc and anti-PDL1-H peptide chains are IgG types, preferably IgG1 subtypes; To avoid the formation of unnecessary homologous dimers in the recombinant expression process of the IAB, a Knob-in-Hole structure is introduced into the Fc segments of the SIRPα-m-Fc and the anti-PDL1-H peptide chains. The “Knob-in-Hole structure” can be achieved by the following: introducing 2 amino acid mutations into the Fc segment of the anti-PDL1-H peptide chain (T366W, S354C) (based on the IgG innate sequence), forming protruded Knob structure. 4 amino acid mutations (Y349C, T366S, L368A, and Y407V) are introduced based on the IgG innate sequence into the Fc segment of the SIRPα-m-Fc peptide chains to form recessed Hole structure, and homologous pairing is prevented by a steric hindrance effect (the EU numbering system of Kabat is used for the above Fc segment amino acid mutation site, i.e., the EU numbering scheme).
- More specifically, the SIRPα-m-Fc peptide chain has the amino acid sequence as set forth in SEQ ID NO: 1; the anti-PDL1-L peptide chain has the amino acid sequence as set forth in SEQ ID NO: 2, and the anti-PDL1-H peptide chain has the amino acid sequence as set forth in SEQ ID NO: 3.
- The IABs can be expressed by genetically engineered CHO (Chinese hamster ovary) cells. Particularly, IABs are expressed by CHO-K1 cells, and the expression vector used is pcDNA3.1(+). The SIRPα-m-Fc is encoded by the nucleotide sequence as set forth in SEQ ID NO: 4; the light chain of the anti-PDL1-L is encoded by the nucleotide sequence as set forth in SEQ ID NO: 5; the anti-PDL1-H is encoded by the nucleotide sequence as set forth in SEQ ID NO: 6; and the sequences as set forth in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6 are inserted by genetic recombination into open reading frame (ORF) of the pcDNA3.1(+), using the constructed expression vector containing the target protein coding sequence to transfect CHO-K1 cells, then screening to obtain the cell strains capable of stably expressing the IAB for the expression of IAB.
- The above-mentioned bifunctional fusion protein targeting CD47 and PD-L1 can be used for manufacturing tumor drugs and immunoregulation drugs.
- Antibodies are produced by the immune system of the body stimulated by antigens. Antibodies are immunoglobulins produced by plasma cell differentiated from B lymphocytes. An antibody is capable of carrying out specific binding reaction with corresponding antigen. Antibodies can also be prepared by in vitro methods such as hybridoma, genetic engineering and the like. According to physical and chemical properties and biological functions, the antibodies can be divided into 5 categories, that is, IgM, IgG, IgA, IgE, and IgD. The IgG (Immunoglobulin G) antibody is the major antibody component in serum, adding up to about 75% of the serum immunoglobulins, and is also the primary type of existing antibody drug inside China and abroad.
- Typically, a complete IgG-type antibody consists of four peptide chains (
FIG. 1 ), including symmetrically two heavy chains and two light chains, and linked together by disulfide bonds. Each light chain consists of variable regions (VLs) and constant regions (CLs), and the heavy chain consists of variable regions (VHs) and constant regions (CHs). The heavy chain constant regions of the IgG-type antibody can be divided into three parts: CH1, CH2, and CH3. The variable regions (VLs and VHs) of the light chain and heavy chain are the moieties binding to the antigen, and the heavy chain CH2, CH3 regions have immune effecting functions such as binding to complement, Fc receptor, protein A, and induces ADCC (antibody dependent cell-mediated cytotoxicity), CDC (complement dependent cytotoxicity) and the like; the CH2 region has a N-linked glycosylation site N297, the glycosylation modification at this site has an important influence on the cytotoxicity of the antibody and the like, and the removal of the said glycosylation will make the antibody lose the function of inducing cytotoxicity such as ADCC. The light chain is linked to the heavy chain through the disulfide bond of the CL and the CH1 regions; the heavy chain is provided with a hinge region between CH1 and CH2 regions, which is easy to stretch and bend, and the two heavy chains of one antibody are connected via disulfide bonds in the hinge region. After the antibody is digested by papain, two Fab (fragments of antigen binding) and 1 Fc (fragment crystallizable) can be formed, wherein the Fab segment contains the complete light chain and heavy chain VH and CH1, and the Fc segment contains CH2 and CH3. - Human IgG has four subtypes: IgG1, IgG2, IgG3 and IgG4, wherein IgG1 has strong ability to induce ADCC and CDC effects and longer serum half-life, and is the most common antibody subtype of antibody drug, such as Rituximab (anti-CD20), Trastuzumab (anti-HER2);
IgG 2 andIgG 4 have weaker abilities to induce ADCC and CDC effects and longer serum half-life, which can be used to develop antibody drugs whose major acting mechanisms are signal blocking, regulatory or neutralizing, such as Nivolumab (anti-PD-1), Pembrolizumab (anti-PD-1). - In order to achieve the purpose of enabling the same antibody molecule to target at two different antigens, CD47 and PD-L1, herein the antibody structure is modified, and an asymmetric fusion protein similar to an antibody structure is constructed through genetic engineering technology (
FIG. 2 ). The fusion protein consists of a CD47 binding moiety and a PD-L1 binding moiety linked by a disulfide bond; wherein the CD47 binding moiety is formed by linking a SIRPα mutant (SIRPα-m) having a high affinity for CD47 and an antibody Fc segment (primarily CH2, CH3 region), and the PD-L1 binding moiety is formed by linking a heavy chain and a light chain of anti-PD-L1 antibody by disulfide bond. - The SIRPα mutant (SIRPα-m) in the fusion protein can bind to the CD47 antigen at much higher affinity than the endogenous natural SIRPα protein, so that the binding of the natural SIRPα on the surface of the macrophage and the CD47 antigen on the surface of cancer cells can be blocked, to avoid the inhibition and escape of cancer cells to the phagocytosis of macrophages.
- The anti-PD-L1 antibody is capable of binding to PD-L1 (highly expressed on the surface of cancer cells) with high affinity, to block the binding of “PD-L1 on the surface of cancer cells to PD-1 on the surface of activated T cells, so that avoid the inhibition and escape of cancer cells to T cells.
- PD-L1 is more highly expressed on cancer cell surface and the targeting property of the anti-PD-L1 is stronger, which make up the deficiencies that the CD47 specificity is poor and the anti-CD47 is severe in blood toxicity. Experiments show that the blood toxicity of the IAB is much lower than that of the fusion protein consisted of SIRPα-m and Fc, and with better safety.
- The bifunctional fusion protein targeting CD47 and PD-L1 of the present disclosure serves both in early innate immunity as to activate macrophage phagocytosis of tumor cells and to improve tumor antigen presentation and in acquired immunity as to promote tumor-specific T cell activation and proliferation, while compared with a single anti-CD47 drug, with better tumor cell targeting and less blood toxicity. Animal experiments shows that the bifunctional fusion protein has better anti-tumor therapeutical effect and blood safety than anti-PD-L1 or anti-CD47 alone. And, the subject with tumor disappeared after IAB treatment can have immunity against the same type of tumor cells inoculated later.
-
FIG. 1 is a schematic (not to scale) illustration of the genomic loci of the representative Cas13e and Cas13f families members. The Cas coding sequences (long bars with pointed end), followed by the multiple nearby direct repeat (DR) (short bars) and spacer sequences (diamonds) are shown. -
FIG. 2 shows putative secondary structures of the DR sequences associated with the respective Cas13e and Cas13f proteins. Their coding sequences, from left to right, are represented by SEQ ID NOs: 8-14, respectively. -
FIG. 3 shows a phylogenetic tree for the newly discovered Cas13e and Cas13f effector proteins of the invention, as well as the related previously discovered Cas13a, Cas13b, Cas13c, and Cas13d effector proteins. -
FIG. 4 shows the domain structures for the Cas13a-Cas13f proteins. The overall sizes, and the locations of the two RXXXXH motifs on each representative member of the Cas proteins are indicated. -
FIG. 5 shows a predicted 3D structure of the Cas13e.1 effector protein. -
FIG. 6 is a schematic drawing showing that the three plasmids, encoding (1) a Cas13e effector protein, (2) a coding sequence for the guide RNA (gRNA) which can produce the guide RNA that is complementary to the mCherry mRNA and that can form a complex with the Cas13e effector protein, and (3) the mCherry reporter gene, respectively, can be transfected to a cell to express their respective gene products, resulting in the degradation of the reporter mCherry mRNA. -
FIG. 7 shows knock-down of mCherry mRNA by guide RNA complementary to the mCherry mRNA, as evidenced by reduced mCherry expression under fluorescent microscope. As a negative control, a non-targeting (NT) guide RNA that does not hybridize with/bind to the mCherry mRNA failed to knock-down mCherry expression. -
FIG. 8 shows about 75% knock-down of mCherry expression in experiments inFIG. 6 . -
FIG. 9 shows that Cas13e utilizes a guide RNA having a DR sequence at the 3′ end (as opposed to a DR sequence at the 5′-end of the guide RNA). -
FIG. 10 shows the correlation between spacer sequence length and specific (guide RNA-dependent) RNase activity against target RNA relative to non-targeting (NT) control. -
FIG. 11 shows the correlation between spacer sequence length and non-specific/collateral (guide RNA-independent) RNase activity against target RNAs relative to non-targeting (NT) control. -
FIG. 12 shows that dCas13e.1-ADAR2DD fusion has RNA base editing activity. Specifically, three plasmids, encoding (1) a dCas13e (RNase dead) protein fused to the single-base RNA editor ADAR2DD, (2) a coding sequence for the guide RNA (gRNA) which can produce the guide RNA that is complementary to a mutant mCherry mRNA having a G-to-A point mutation and that can form a complex with the dCas13e effector protein, and (3) the mutant mCherry reporter gene encoding the mCherry mRNA having the G-to-A point mutation, respectively, can be transfected to a cell to express their respective gene products. The mutant mCherry mRNA normally cannot produced a fluorescent mCherry protein due to the point mutation. Upon guide RNA binding to the mutant mCherry mRNA, the fused ADAR2DD base editor converts A to I (G equivalent), thus restoring the ability of the mRNA to encode a fluorescent mCherry protein. -
FIG. 13 shows restored expression of mCherry as a result of successful RNA base editing. In the Experiment inFIG. 12 , plasmid encoding mutant mCherry (mCherry*) alone failed to express fluorescent mCherry. Plasmid encoding dCas13e-ADAR2DD base editor alone also failed to express fluorescent mCherry. Plasmid encoding either gRNA-1 or gRNA-2 alone (which also expresses a GFP reporter) also failed to express fluorescent mCherry, though GFP was expressed prominently. However, when all three plasmids were transfected into the same cell, significant fluorescent mCherry expression was observed (together with GFP reporter expression). -
FIG. 14 shows the relevant segment of the mutant mCherry gene having the premature stop codon TAG, the sequence for the two gRNA that can be complexed with the dCas13e-ADAR2DD RNA base editor, and the “corrected” TGG codon. -
FIG. 15 is a schematic (not to scale) drawing showing the series of progressive C-terminal deletion constructs for dCas13e.1 fused to the ADAR2DD RNA base editor (shown as “ADAR2”), as well as other transcriptional control elements. -
FIG. 16 shows the percentage results of mCherry mutant conversion back to wild-type mCherry, for the series of C-terminal deletion mutants inFIG. 15 . -
FIG. 17 is a schematic (not to scale) drawing showing the series of progressive C-terminal and optional N-terminal deletion constructs for dCas13e.1 fused to the ADAR2DD RNA base editor. -
FIG. 18 shows the percentage results of mCherry mutant conversion back to wild-type mCherry, for selected C- and N-terminal deletion mutants inFIG. 17 . -
FIG. 19 shows the series of plasmids encoding Cas13a, Cas13b, Cas13d, Cas13e.1 and Cas13f.1, the mCherry reporter gene, as well as either the ANXA4-targeting gRNA coding sequence, or a non-targeting gRNA as control. -
FIG. 20 shows efficient knock-down of ANXA4 expression by Cas13e.1, Cas13f.1, Cas13a, as well as Cas13d. - According to nucleic acids as set forth in SEQ ID NO: 4 (encoding a fusion peptide formed by linking SIRPα mutant with antibody Fc segment, with Hole structure formed by the mutation of Y349 C, T366S, L368 A and Y407 V), SEQ ID NO: 5 (encoding anti-PD-L1 antibody light chain), and SEQ ID NO: 6 (encoding anti-PD-L1 antibody heavy chain, with Knob structure formed by mutations of T366W and S354C), corresponding DNA fragments were synthesized respectively, and were inserted into the pcDNA3.1 (+) vector by genetic engineering technology. The expression vectors constructed were called as pcDNA3.1-SIRPα-m-Fc, pcDNA3.1-antiPDL1-L and pcDNA3.1-antiPDL1-H. Three expression vectors were co-transfected with liposomes into CHO-K1 host cells, and the transfected cells were cultured in DMEM complete medium containing 20% fetal bovine serum (FBS) (available from Invitrogen Inc.) for 24 hours, and then screened under pressure in selection medium containing 1 mg/ml G418, continued for incubation for 2 weeks. Subcloning screening was carried out by limited dilution assay; comparing the content of the target protein in the cell culture supernatant by Dot-Blot assay (the supernatant is blotted on a nitrocellulose membrane, and then adding a horseradish peroxidase (HRP)-labeled mouse anti-human Ig antibody, and colored by diaminobenzidine DAB after sealing), and screening a clone with the highest expression of the target protein IAB as the expression cell strain.
- The expression cell strains were passaged in a mixed culture medium consisting of DMEM complete medium and CHOM-B1 serum-free medium (available from Shanghai SINOMAB biotech Ltd., Shanghai) of different ratios, and the ratio of complete medium was reduced from 100% to 0%, and then continued the culture in CHOM-B1 serum-free medium for passage. When the cell culture volume was increased to 6 L, passage was stopped, flow feeding was carried out, for which glucose was added according to 2 g/L per day, supernatant was collected after 7 days, centrifuged at 9000 rpm and 4° C. for 10 min. The precipitate was discarded, the supernatant was filtered with 0.2 microfilm, and kept at 4° C. for purification.
- The bifunctional fusion protein IAB was purified by Protein A affinity chromatography column method, a balance liquid of 10 times of column volume (20 mM phosphate buffer solution containing 150 mM NaCl, pH 7.0) was used for balancing the column body and then loading the supernatant. After loading, the column was washed by balance buffer of 5-10 times of the column volume to the conductance balance. Elution was then carried out with eluent (50 mM citric acid buffer, pH 3.5) and the elution peak was collected after OD 280 was greater than 200 mAU. After the eluent containing the target protein was regulated with 1M Tris to pH6.5-7.0, gel desalination column replacement buffer (pH 7.4 phosphate buffer) were used, followed by sterilizing filtration. Detected the protein concentration by UV method and stored at 4° C. for later use.
- Complete protein molecular weight and reduced molecular weight were detected by polyacrylamide gel electrophoresis (SDS-PAGE) under conditions of non-reducing (8% separating gel) and reducing (12% separating gel), respectively, by using purified antibody samples. The reagent formulation and operating method can refer to “Molecular Cloning: A laboratory Guide”. The electrophoresis results are shown in
FIG. 3 (non-reduced SDS-PAGE) andFIG. 4 (reduced SDS-PAGE) in the figures of the specification. - In the non-reduced SDS-PAGE electrophoresis diagram of
FIG. 3 , the complete protein molecular weight of the target protein IAB was about 120 kDa; in the reduced SDS-PAGE electrophoresis diagram ofFIG. 4 , the partial molecular weight of the heavy chain of the IAB protein (anti-PDL1-H) was about 50 kDa, and the fusion peptide chain (SIRPα-m-Fc) has a partial molecular weight of about 40 kDa, the light chain (anti-PDL1-L) moiety was 25 kDa, which is substantially consistent with the theoretical value. The fusion peptide chain (SIRPα-m-Fc) inFIG. 4 exhibits two bands of about 40 kD, which may be associated with the effect of post-translational modifications and spatial structure on electrophoresis. - The expressed and purified IAB fusion protein was desalted into 50 mM NH4HCO3 solution, and the desalted protein solution was quantified by UV (50 mM NH4HCO3 as blank control with an extinction coefficient of 1.60). The desalted protein solution was added to 50 mM NH4HCO3, diluted to 1 mg/mL for loading.
- Liquid Chromatography Conditions:
- Liquid Phase Equipment, Waters ACQUITY UPLC system; chromatographic measures: BEH 300.4 C4 1.7 μm, 2.1×50 mm;
column temperature 60° C.;sample chamber temperature 15° C.; flow rate 0.4 ml/min; mobile phase A: 99.9% water+0.1% formic acid; mobile phase B: 99.9% acetonitrile+0.1% formic acid; loading volume: 5 μL; detector ESI-Q-TOF. - Mass Spectrum Conditions:
- mass spectrometry equipment: Waters;
source temperature 120; capillary voltage setting: 3000V; primary cone voltage setting: 40 V; secondary cone voltage setting: 4V; cone gas flow rate: 50 L/H; acquisition time range 3-15 min; desolvation temperature setting: 400° C. quality calibration range selection: 500-3000m/z; acquisition quality range selection 500-3000 m/z; scan time: 1.0 S. - The results are shown in
FIG. 5 . The main sugar types modified after IAB translation are −2KG0F(2)(molecular weight 113785), −2KG0FG1F (molecular weight 113949), −2KG1F(2)(molecular weight 114114), G0G2F (114216), without significant production of undesirable sugar types. Its molecular weight and theoretical molecular weight (post-translational modification) are consistent. - According to nucleotide sequences of SEQ ID NO:9 (encoding the fusion peptide formed by linking SIRPα high affinity mutant SIRPα-m and IgG1 antibody Fc, but without “Hole” structure) and SEQ ID NO: 10 (encoding heavy chain of anti-PD-L1 antibody, but without “Knob” structure, and the Fc glycosyl modification was removed by N297A mutation), corresponding DNA fragments were synthesized, and inserted into the pcDNA3.1 vector respectively to construct expression vectors pcDNA3.1-SIRPα-m-Fc′ and pcDNA3.1-antiPDL1-H ‘.
- The pcDNA3.1-SIRPα-m-Fc’ was transfected into CHO-K1 expression host cells according to the method of Example 1. The strains of high expression were screened, and the control SIRPα-m-Fc fusion protein was prepared by using the protein expression and purification methods in Examples 1 and 2, and the protein was named as SIRPα-m-Fc′ with the amino acid sequence as set forth in SEQ ID NO: 7.
- A control anti-PD-L1 antibody was prepared by co-transfect pcDNA3.1-antiPDL1-H′ and pcDNA3.1-antiPDL1-L prepared in Example 1 into CHO-K1 expression host cell and screen cell strain with high expression. Protein expression and purification method in Examples 1 and 2 was used to prepare said control antiPD-L1 antibody, which was called anti-PDL1′ with the amino acid sequence as set forth in SEQ ID NO: 8.
- (1) The Determination of the Binding Ability of IAB to Human PD-L1 by Competitive ELISA
- Biotin labeled anti-PDL1′ was used. The recombinant expressed human PD-L1-Fc fusion protein was diluted with 0.1M NaHCO3 solution (pH9.6) to 5 μg/ml, and coated the microwell plates at 100 μl/well, washed, blocked, and then biotin-labeled anti-PDL1′ and gradient diluted competitors were added into each well, wherein the competitors were unlabeled anti-PDL1′ or IAB proteins prepared in Example 2. The competitor concentrations were respectively initiated from 1 μg/ml, and 2-fold diluted. Each concentration was repeated in triplicate wells, incubated at 37° C. for 1 hour, and then the reaction liquid was discarded, plates were washed. Avidin-labeled horseradish peroxidase (Avidin-HRP) and substrate TMB were added for developing, OD450 nm absorbence was measured. The results were plotted and shown in
FIG. 6 . The x axis is competitor concentration (ng/ml) and the y axis is OD value, hollow triangle is competition data of anti-PDL1′, and the solid circle is competition data of IAB. -
TABLE 1 Competitive ELISA Assay Results of IAB Fusion Protein and anti-PDL1′ Parameter Estimated value S.D Confidence interval Result of anti-PDL1′ A 2.119 0.019 [2.080, 2.158] competitive binding B 0.939 0.024 [0.889, 0.989] R2 = 0.999 C 0.948 0.029 [0.889, 1.007] IC50 = 0.948 D 0.001 0.010 [−0.019, 0.021] Result of IAB competitive A 1.999 0.011 [1.976, 2.022] binding B 0.912 0.028 [0.854, 0.970] R2 = 0.999 C 11.76 0.425 [10.89, 12.63] IC50 = 11.76 D −0.028 0.020 [−0.069, 0.014] - (2) The Binding Ability of IAB with Human CD47 Determined by Competitive ELISA
- The binding of IAB protein to CD47 was determined by the same method, The antigen coating microwell plate was a recombinant expressed human CD47 protein, Biotin-labeled SIRPα-m-Fc′ and gradient diluted competitors were added. The competitors were unlabeled SIRPα-m-Fc′ or IAB proteins prepared in Example 2. The competitor concentrations were respectively initiated from 1 μg/ml, and 2-fold diluted. Each concentration was repeated in triplicate wells, after incubation, horseradish and TMB were used for developing, OD450 nm absorbance was measured. The results were plotted and shown in
FIG. 7 . The x axis is competitor concentration (ng/ml) and the y axis is OD value, hollow triangle is competition data of anti-PDL1′, and the solid circle is competition data of IAB. -
TABLE 2 Competitive ELISA Assay Results of IAB fusion protein with SIRPα-m-Fc′ Parameter Estimated value S.D Confidence interval Results of SIRPα-m- A 1.166 0.015 [1.136, 1.196] Fc′ competitive binding B 1.770 0.105 [1.554, 1.987] R2 = 0.996 C 0.918 0.035 [0.846, 0.991] IC50 = 0.918 D 0.007 0.009 [−0.011, 0.026] Results of IAB A 1.154 0.011 [1.131, 1.177] competitive binding B 1.513 0.078 [1.352, 1.673] R2 = 0.997 C 2.897 0.111 [2.688, 3.127] IC50 = 2.897 D 0.013 0.010 [−0.008, 0.033] - The results of
FIGS. 6 and 7 illustrate that fusion protein IAB has binding activity to both target antigens PD-L1 and CD47 at the same time, and recognizes the same binding epitope as prototype antibody or ligand, having competitive binding capacity. However, since the IAB protein and binding site are “monovalent”, its affinity is reduced compared to the prototype antibody or ligand. The affinity of IAB (IC50=11.76) to PD-L1 was reduced by nearly 10 times compared to the affinity of PD-L1′ (IC 50=0.948); and the affinity of IAB to CD47 (IC50=2.897) was reduced by approximately 3 times compared to the affinity of SIRPα-m-Fc′ (IC50=0.918). - (3) Flow Cytometry Assay for Binding Ability of IAB Protein to Cancer Cells
- The binding of IAB protein to MC38 cells (mouse colon cancer cells), HL60 cells (human leukemia cells) was detected using flow cytometry and the results are shown in
FIGS. 19 and 20 (dotted lines represent blank controls, and solid lines represent IAB proteins, short dashed lines represent anti-PDL1′, and long dashed lines represent SIRPα-m-Fc′) using SIRPα-m-Fc′ and anti-PDL1′ as control. The results illustrate that the IAB protein can bind to the surface of MC38 cell and the HL60 cells. - 20 ml of healthy human venous blood is collected and density gradient centrifuge was used to separate peripheral blood mononuclear cells (PBMC). PBMC was re-suspended in RPMI 1640 medium containing 10% FBS, plated onto 96-well cell culture plates at 1×105 cells/well and then added to each well RPMI1640 medium comprising different concentrations (0.01 ng/mL, 0.1 ng/mL, 1 ng/mL, 10 ng/mL, 100 ng/mL) Staphylococcus enterotoxin B (SEB) and 20 μg/ml associated protein (IAB, anti-PDL1′ or SIRPα-m-Fc′), incubated for 72 h in 37° C., 5% CO2 incubator. The cell status was observed by an inverted microscope on a daily basis. The supernatant was taken after 72 hours, and the amount of IL-2 secretion was determined by ELISA. Experimental results are shown in
FIG. 8 . The stimulation of PBMC cells by SEB can increases its IL-2 secretion amount and exhibits a dose-dependent profile within a certain concentration range of SEB (0-100 ng/mL). The IL-2 amount of IAB and anti-PDL1′ groups at different SEB concentrations are significantly higher than SIRPα-m-Fc′. It is proved that the IAB can activate T cells in vitro. - 2×106 mouse colon cancer cell strain MC 38 was incubated with 2000 μL of 5 μM CSFE (2-carboxyfluorescein diacetate succinimidyl ester, a live fluorescent dye) solution at 37° C. for 20 min, and then 10 mL of complete medium was added, incubated for 5 min to remove unbound CSFE in the solution. The marked tumor cells were collected by centrifugation and resuspended in complete medium to prepare tumor cell suspension at a concentration of 1×106/mL.
- 1 ml of 5×104 cell/ml mouse macrophage RAW264.7 (ATCC TIB-71) suspension was added to each well in a 24-well plate. After the macrophages were attached to the wall, the culture medium in the well plate was discarded, and then serum-free culture medium was added for incubation for 2 hours. Then, CFSE-labeled tumor cells (2×105) were added into each well, while adding IAB protein, control SIRPα-m-Fc′, anti-PDL1′, i.v. human immunoglobulin (IgG1, available from China Biologic Products Holdings, Inc.) at final concentration of 10 μg/ml, incubated at 37° C. for 2h.
- Macrophages were digested with Trypsin and then collected by centrifugation, washed twice with PBS. After counted on Hemocytometer, the cell density was adjusted to 1×106/mL and resuspended in PBS buffer containing 1% FBS. Cell suspension was then added to flow cytometry assay tube (100 μL/tube), centrifuged to discard supernatant, and 100 μL of fluorescent labeled antibody (PE-labeled anti-mouse F4/80 antibody) was added to the flow cytometry tube, incubated on ice in dark for 45 min, washed twice with PBS buffer containing 1% FBS and assay in the suspension in 300 μl PBS. PE mono-positive was macrophages, CSFE mono-positive was MC38 tumor cells, PE and CSFE double-positive cells were macrophages for phagocytosis of MC38 cells. Phagocytosis rates of macrophages under the action of different proteins were calculated.
- The experimental results are shown in
FIG. 9 . In macrophage-tumor cell co-culture system, the macrophage phagocytosis efficiency in the co-culture system is substantially the same (<10%) when comparing anti-PDL1′ to the negative control (IgG1). While for positive control (SIRPα-m-Fc′) and IAB fusion protein, the phagocytosis efficiency of macrophages in the co-culture system can be greatly improved, wherein the phagocytosis promoting ability of the IAB fusion protein (36%) is lower than SIRPα-m-Fc′ (49%), while anti-PDL1′ does not have the ability to promote the macrophage phagocytosis. - To further verify the phagocytosis promoting ability of IAB fusion protein on macrophages derived from mouse myeloid, mouse myeloid cells were isolated and cultured for 7-10 days with the induction of 50 ng/ml M-CSF to prepare mouse myeloid-derived macrophages. 5×104 mouse myeloid-derived macrophages were mixed with 2×105 CFSE-labeled MC38 tumor cells, adding into IAB fusion protein, negative control (IgG1) and positive control SIRPα-m-Fc′, incubated at 37° C. for 2 hours, photographed with an inverted microscope, and macrophages with green fluorescence in the image were macrophages after phagocytosis of tumor cells. As shown in
FIG. 10 , macrophages (FIG. 10a ) adhere to the wall and stretch out the pseudopods in the negative control group added with IgG1 (FIG. 10a ), almost no macrophages phagocytized tumor cells (green fluorescence). In IAB combination (FIG. 10c ) and positive control group SIRPα-m-Fc′ (FIG. 10b ), the macrophages phagocytized tumor cells (green fluorescence) (indicated by the black arrows). The above results again verify that the IAB fusion protein has the ability to promote macrophage phagocytosis of tumor cells in vitro. - Different concentrations of antibodies to be tested (IAB fusion protein, positive control SIRPα-m-Fc′, negative control anti-PDL1′) were incubated with Jurkat cells (effector cells) expressing FcγIIIa transformed by luciferase reporter gene and MC38 tumor cells (target cells), incubated at 37° C. in an incubator with 8% CO2 for 4 h; the fluorescent substrate was added, Fluorescence readings were measured on Glomax® well plate fluorescence assay ELISA, and the results are shown in
FIG. 11 . - The black squares in
FIG. 11 are data for IAB fusion proteins. The black solid circles are the data of SIRPα-m-Fc′, and the black triangles are the data of anti-PDL1′. The data illustrated that the IAB fusion protein has certain ADCC effect, but the ADCC effect thereof at equivalent doses is lower than that of SIRPα-m-Fc′, possibly in relation to the Knob-in-Hole structure. Because of the introduction of N297A mutation into the conservative glycosylation site in antibody Fc segment and without glycosyl modification, the ADCC effect is lost. - 15 healthy Balb/c mice (6-8 weeks) were randomly divided into 3 groups (5 per group) by weight (on average about 20 g). Each group of mice were administered intraperitoneally (IAB, SIRPα-m-Fc′, or i.v. human IgG) at a dose of 100 mg/kg; after 24 hours of administration, mice were sampled for blood through the orbital about 500 μl into EP tube, and 1
% heparin sodium 10 μL was added immediately to prevent clotting. Mouse blood analysis was performed at Shanghai Model Organisms Center, Inc. By monitoring the change of indexes such as red blood cells, blood proteins, red blood cell specific volume, platelets and the like in mice blood after administration, blood toxicity of prototype antibody and IAB fusion protein were evaluated, and the results are shown inFIG. 12 ,FIG. 13 , andFIG. 14 . The results suggest that red blood cell content (9.1×1012/L), HCT (43.0%), hemoglobin (137.8 g/L) of the experimental group injected with IAB protein do not have significant difference from the red blood cell content (9.4×1012/L), HCT (42.56%), and hemoglobin (142.4 g/L) of the control group injected with human IgG. Whereas the group injected with SIRPα-m-Fc′ was affected by the blood toxicity, the relevant data are redblood cell content 8×1012/L, HCT 35.07%, and hemoglobin 121.6 g/L, which are significantly different from the other two groups. - (1) The IAB Treatment of Balb/c Mice MC38 Tumor Model:
- Balb/c female mice (6-8 weeks) were inoculated with MC38 tumor cells (2×105 cells/animal) subcutaneously, total 40 mice. After removing mice with too large or too small tumors on
day 6, the remaining mice were grouped into 4 groups according to the tumor volume (about 100 mm3), eachgroup 8 mice. IAB fusion protein, irrelevant control (human IgG1), or the prototype antibody (SIRPα-m-Fc′, anti-PDL1′) were injected into the tumor at 10 mg/kg. Tumor formation in mice were observed twice a week, using calipers to measure the maximum diameter (length) and the vertical distance (width) of the tumor, with the calculation formula for tumor volume: volume=0.5×length×width2. When the tumor volume in mice was greater than 2000 mm3, or large area of ulcer appeared at the tumor site, the mice were sacrificed by cervical dislocation. The observation usually lasts 21 days. The experimental results are shown inFIG. 15 . - The experimental results show that after the control group was administered with irrelevant antibodies (i.v. human IgG1), the tumor was in progressive growth, and the average volume of tumor on
day 21 reached 1472 mm3 at the end of observation (21 days after inoculation), the control group and the SIRPα-m-Fc′ treatment group mice were dispirited, thin, wrinkled skin and with slow movement. The tumor on the back of the anti-PDL1′ and IAB treatment group mice were shrunk to various extent. The average tumor size of anti-PDL1′ treatment group mice is 289 mm3. The average tumor size of IAB treatment group mice is 67 mm3, and tumor in some of the mice completely disappeared, indicating that IAB fusion protein has better anti-tumor effect than prototype protein (anti-PDL1′ and SIRPα-m-Fc′) in the treatment of MC38 tumor model. The tumor suppressing effect is with the following order: IAB>anti-PDL1′>SIRPα-m-Fc′. The result shows that under same dosage and with same administration route, the IAB fusion protein has a “synergistic effect” of tumor suppression. - (2) IAB Prevent Tumor in the Balb/c Mice Inoculated with MC38 Tumor Model (Secondary Inoculating):
- Mice treated with IAB fusion protein treatment groups whose tumor completely disappeared (touching inoculation sites with no accessible tumors) and healthy BALB/c mice were subjected to MC38 secondary inoculation experiment. MC38 tumor cells were inoculated subcutaneously on the other side of the primary inoculation site in mice, with the inoculum size of 2×105 cells/animal. Tumor formation in mice were observed twice a week, using calipers to measure the maximum diameter (length) and the vertical distance (width) of the tumor, with the calculation formula for tumor volume: volume=0.5×length×width2. When the tumor volume in mice was greater than 2000 mm3, or large area of ulcer appeared at the tumor site, the mice were sacrificed by cervical dislocation. The observation usually lasts 21 days. The experimental results are shown in
FIG. 16 . - The experimental results showed that after the control group (healthy Balb/c mice) was inoculated with MC38 cells, the tumor was in progressive growth, and the average volume of tumor on
day 21 reached 1453 mm3; however, after the mice cured with IAB fusion protein were inoculated with MC38, no accessible tumor (less than 30 mm3) can be found at the inoculation site within 21 days. Only one mouse had evidence of tumor growth onday 10, but disappeared itself later. The above results showed that it is possible that the cured mice have alleviate the tumor adaptability for MC38 and the inhibitory state of innate immunity, and the antigen-specific T cells generated after the adaptive immune activation can inhibit the tumor formation of the MC38 tumor cells for a second time. - (1) IAB Treatment for MC38 Tumor-Bearing Mice (Macrophage Defective Type):
- MC38 tumor cells were inoculated subcutaneously to 15 BALB/C healthy female mice of 6-8 weeks at 2×105 cells. On
day 6, mice were grouped according to the mean tumor volume into three groups, each group consisting of 5 mices, and assigned as experimental group,control group 1, andcontrol group 2. Experimental group were injected with Clophosome (a macrophage remover, available from Shanghai BangLv Biotech Co., Ltd) at 200 μL/mouse, then 100 μl/mouse every other day; IAB fusion protein were injected into the tumor at 10 mg/kg dose onday 7 andday 10.Control group 1 were injected with blank liposome instead of Clophosome to inject mouse, and IAB fusion protein were injected into the tumor at 10 mg/kg dose onday 7 andday 10;Control Group 2 were injected with blank liposome instead of Clophosome, and irrelevant human IgG antibody was injected into the tumor at 10 mg/kg dose onday 7 andday 10. Tumor formation in mice were observed twice a week, using calipers to measure the maximum diameter (length) and the vertical distance (width) of the tumor, with the calculation formula for tumor volume: volume=0.5×length×width2. When the tumor volume in mice was greater than 2000 mm3, or large area of ulcer appeared at the tumor site, the mice were sacrificed by cervical dislocation. The observation usually lasts 21 days. The experimental results are shown inFIG. 17 . - The experimental results show that after the mice without removal of macrophages were injected with irrelevant antibodies (that is, control group 2), the subcutaneous tumor was in progressive growth, and the average volume of tumor on
day 20 reached 1419 mm3. After administration of IAB fusion protein (that is, the control group 1), the tumor in the mice without removal of macrophages was effectively inhibited, the average size of tumor onday 20 was only 55.8 mm3. After IAB fusion protein administration, the mice with removal of macrophage (that is, the experimental group) although have partly inhibited tumor growth, and the average tumor size onday 21 is 587 mm3, the tumor inhibitory effect is significantly lower than the healthy mice group (control group 1). The above experiment suggests that the in vivo tumor inhibitory effect of IAB fusion protein depends on the innate immune cells (Macrophages). - (2) Treatment of MC38 Tumor Bearing Mouse (CD8+ T Cell Defective Type) by IAB:
- Each BALB/c mouse was injected twice weekly with anti-CD8 antibodies or irrelevant IgG antibodies (200 μg/mouse/time) to remove CD8+ positive T cells in mice.
- MC38 tumor cells were inoculated subcutaneously to 5 Balb/c mice with the removal of CD8+ T cells (experimental group), 10 healthy female mice (divided into
control groups 1 and 2) of 6-8 weeks at 2×105 cells. Onday 6, experimental group andcontrol group 1 were injected with IAB fusion protein in tumor at 10 mg/kg dose onday 7 andday 10.Control group 2 was injected with irrelevant human IgG antibodies at 10 mg/kg dose in tumor onday 7 andday 10. Tumor formation in mice were observed twice a week, using calipers to measure the maximum diameter (length) and the vertical distance (width) of the tumor, with the calculation formula for tumor volume: volume=0.5×length×width. When the tumor volume in mice was greater than 2000 mm3, or large area of ulcer appeared at the tumor site, the mice were sacrificed by cervical dislocation. The observation usually lasts 21 days. The experimental results are shown inFIG. 18 . - In the experimental results, after the irrelevant antibody was administered to the mice without removal of CD8+ T cells, the MC38 tumor size was in progressive increase, and the average volume of tumor on
day 21 reached 1269 mm3. After IAB fusion protein was administrated to the mice without removal of CD8+ T cells (control group 1), the tumor was effectively inhibited, the average volume of tumor onday 21 was only 64.9 mm3. After the administration of IAB fusion protein, the mice with removal of CD8+ T cells (the experimental group) have average tumor volume of 777 mm3 onday 21, whose tumor inhibitory effect is significantly lower than the healthy mice IAB administration group (Experimental group). The above experiment results suggest that the in vivo tumor inhibitory effect of IAB fusion protein also depends on the adaptive immune cells (CD8+ T cells).
Claims (10)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2017/111828 WO2019095358A1 (en) | 2017-11-20 | 2017-11-20 | Bifunctional fusion protein targeting cd47 and pd-l1 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200354458A1 true US20200354458A1 (en) | 2020-11-12 |
Family
ID=66539296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/765,008 Pending US20200354458A1 (en) | 2017-11-20 | 2017-11-20 | Bifunctional Fusion Protein Targeting CD47 and PD-L1 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20200354458A1 (en) |
EP (1) | EP3715377A4 (en) |
JP (1) | JP7163399B2 (en) |
AU (1) | AU2017439776A1 (en) |
BR (1) | BR112020010020A2 (en) |
CA (1) | CA3084391C (en) |
WO (1) | WO2019095358A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112641953A (en) * | 2019-10-10 | 2021-04-13 | 复旦大学 | Targeting functional molecule modified antibody compound |
CN113321735A (en) * | 2021-05-20 | 2021-08-31 | 盛禾(中国)生物制药有限公司 | Multifunctional fusion protein |
WO2022148411A1 (en) * | 2021-01-08 | 2022-07-14 | 北京韩美药品有限公司 | Anti-pd-1/anti-cd47 natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof |
US11702474B2 (en) | 2019-12-17 | 2023-07-18 | Pfizer Inc. | Antibodies specific for CD47, PD-L1, and uses thereof |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108588126B (en) | 2017-03-31 | 2020-04-10 | 北京百奥赛图基因生物技术有限公司 | Preparation method and application of humanized modified animal model of CD47 gene |
AU2018378529A1 (en) * | 2017-12-04 | 2020-06-18 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anti-PD-L1/anti-CD47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof |
AU2020296785A1 (en) | 2019-06-19 | 2022-01-20 | Lepu Biopharma Co., Ltd. | Anti-CD47 antibodies and uses thereof |
WO2020259605A1 (en) * | 2019-06-25 | 2020-12-30 | 信达生物制药(苏州)有限公司 | Formulations containing anti-cd47/pd-l1 bispecific antibody and preparation method therefor and use thereof |
CN113122574A (en) * | 2019-12-31 | 2021-07-16 | 百奥赛图(北京)医药科技股份有限公司 | Construction method of immunodeficiency humanized non-human animal |
CN113773401B (en) * | 2021-09-15 | 2023-06-20 | 宜明昂科生物医药技术(上海)股份有限公司 | Recombinant fusion protein targeting CD47 and PD-L1 and preparation and application thereof |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100203056A1 (en) * | 2008-12-09 | 2010-08-12 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
US8597911B2 (en) * | 2003-06-11 | 2013-12-03 | Chugai Seiyaku Kabushiki Kaisha | Process for producing antibodies |
US20160229913A1 (en) * | 2014-05-02 | 2016-08-11 | Momenta Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS |
US9447159B2 (en) * | 2011-04-29 | 2016-09-20 | Roche Glycart Ag | Immunoconjugates |
US20170107270A1 (en) * | 2015-08-07 | 2017-04-20 | Alexo Therapeutics Inc. | Constructs having a sirp-alpha domain or variant thereof |
US10035855B2 (en) * | 2015-03-04 | 2018-07-31 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD47 |
US10059769B2 (en) * | 2016-06-13 | 2018-08-28 | I-Mab | Anti-PD-L1 antibodies and uses thereof |
US11634490B2 (en) * | 2018-06-15 | 2023-04-25 | Accurus Biosciences, Inc. | Blocking antibodies against CD47 and methods of use thereof |
US11672859B2 (en) * | 2021-09-15 | 2023-06-13 | Immuneonco Biopharmaceuticals (Shanghai) Inc. | Recombinant fusion proteins targeting CD47 and PD-L1, preparation and use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4116331A1 (en) * | 2012-12-17 | 2023-01-11 | PF Argentum IP Holdings LLC | Treatment of cd47+ disease cells with sirp alpha-fc fusions |
PT3180363T (en) * | 2014-08-15 | 2019-11-05 | Merck Patent Gmbh | Sirp-alpha immunoglobulin fusion proteins |
WO2016187226A1 (en) * | 2015-05-18 | 2016-11-24 | Ab Initio Biotherapeutics, Inc. | Sirp polypeptide compositions and methods of use |
ES2789500T5 (en) * | 2015-05-29 | 2023-09-20 | Hoffmann La Roche | Therapeutic and diagnostic procedures for cancer |
CN107459578B (en) * | 2016-05-31 | 2021-11-26 | 泰州迈博太科药业有限公司 | Difunctional fusion protein targeting CD47 and PD-L1 |
CN106519036B (en) * | 2016-11-04 | 2019-06-11 | 新乡医学院 | The bifunctional protein and the preparation method and application thereof of anti-CD47 and EGFR |
-
2017
- 2017-11-20 JP JP2020545405A patent/JP7163399B2/en active Active
- 2017-11-20 CA CA3084391A patent/CA3084391C/en active Active
- 2017-11-20 BR BR112020010020-0A patent/BR112020010020A2/en unknown
- 2017-11-20 WO PCT/CN2017/111828 patent/WO2019095358A1/en unknown
- 2017-11-20 EP EP17931926.4A patent/EP3715377A4/en active Pending
- 2017-11-20 AU AU2017439776A patent/AU2017439776A1/en active Pending
- 2017-11-20 US US16/765,008 patent/US20200354458A1/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8597911B2 (en) * | 2003-06-11 | 2013-12-03 | Chugai Seiyaku Kabushiki Kaisha | Process for producing antibodies |
US20100203056A1 (en) * | 2008-12-09 | 2010-08-12 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
US9447159B2 (en) * | 2011-04-29 | 2016-09-20 | Roche Glycart Ag | Immunoconjugates |
US20160229913A1 (en) * | 2014-05-02 | 2016-08-11 | Momenta Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS |
US10035855B2 (en) * | 2015-03-04 | 2018-07-31 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD47 |
US20170107270A1 (en) * | 2015-08-07 | 2017-04-20 | Alexo Therapeutics Inc. | Constructs having a sirp-alpha domain or variant thereof |
US10059769B2 (en) * | 2016-06-13 | 2018-08-28 | I-Mab | Anti-PD-L1 antibodies and uses thereof |
US11634490B2 (en) * | 2018-06-15 | 2023-04-25 | Accurus Biosciences, Inc. | Blocking antibodies against CD47 and methods of use thereof |
US11672859B2 (en) * | 2021-09-15 | 2023-06-13 | Immuneonco Biopharmaceuticals (Shanghai) Inc. | Recombinant fusion proteins targeting CD47 and PD-L1, preparation and use thereof |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112641953A (en) * | 2019-10-10 | 2021-04-13 | 复旦大学 | Targeting functional molecule modified antibody compound |
US11702474B2 (en) | 2019-12-17 | 2023-07-18 | Pfizer Inc. | Antibodies specific for CD47, PD-L1, and uses thereof |
WO2022148411A1 (en) * | 2021-01-08 | 2022-07-14 | 北京韩美药品有限公司 | Anti-pd-1/anti-cd47 natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof |
CN113321735A (en) * | 2021-05-20 | 2021-08-31 | 盛禾(中国)生物制药有限公司 | Multifunctional fusion protein |
Also Published As
Publication number | Publication date |
---|---|
JP2021511817A (en) | 2021-05-13 |
EP3715377A1 (en) | 2020-09-30 |
JP7163399B2 (en) | 2022-10-31 |
WO2019095358A1 (en) | 2019-05-23 |
EP3715377A4 (en) | 2021-06-02 |
CA3084391C (en) | 2023-10-10 |
CA3084391A1 (en) | 2019-05-23 |
BR112020010020A2 (en) | 2020-11-10 |
AU2017439776A1 (en) | 2020-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200354458A1 (en) | Bifunctional Fusion Protein Targeting CD47 and PD-L1 | |
AU2015303164B2 (en) | Combination therapies with anti CD40 antibodies | |
WO2018036473A1 (en) | Anti-ctla4 and anti-pd-1 bifunctional antibody, pharmaceutical composition thereof and use thereof | |
EP3858856A1 (en) | Anti-b7-h3 monoclonal antibody and use thereof in cell therapy | |
JP5960597B2 (en) | Combined immunotherapy for cancer treatment | |
AU2022201762A1 (en) | IL-15 variants and uses thereof | |
CN107903324B (en) | Bispecific antibody capable of binding to human CD19 and CD3 | |
JP2020520249A (en) | Bispecific recombinant protein and its application | |
US10759859B2 (en) | Anti-PD-1 antibodies and uses thereof | |
TWI793325B (en) | Antibodies specific for cd3 and uses thereof | |
CN109232740B (en) | anti-PD-L1 antibody and application thereof in anti-tumor treatment | |
WO2024012457A1 (en) | Trispecific antibody and use thereof | |
CN114026122A (en) | Multifunctional molecules that bind to T cell-associated cancer cells and uses thereof | |
JP2024513262A (en) | Bispecific antibodies targeting NKP46 and CD38 and methods of use thereof | |
CN114316045A (en) | anti-PD-L1 antibodies and uses thereof | |
US11795230B2 (en) | Anti-CD27 antibodies and use thereof | |
CN114014938B (en) | Chimeric Antigen Receptor (CAR) and application thereof | |
WO2024051223A1 (en) | Pharmaceutical composition and use thereof | |
WO2023088337A1 (en) | Bispecific antibody against tigit and pd-l1, and pharmaceutical composition thereof and use thereof | |
AU2022350320A1 (en) | Fusion protein dimer including pd-1 and il-21, and use thereof | |
BR112017002729B1 (en) | COMBINATION THERAPY KIT FOR TREATING A SOLID TUMOR IN AN INDIVIDUAL, ANTIBODY OR ANTIGEN-BINDING PORTION THEREOF, USE AND PHARMACEUTICAL COMPOSITION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TAIZHOU MABTECH PHARMACEUTICAL CO., LTD., CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GUO, YAJUN;REEL/FRAME:052689/0556 Effective date: 20200424 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |